Skip to main content

Table 4 Predefined cohorts of interest

From: Predictors of response to fixed-dose vasopressin in adult patients with septic shock

Cohort of interest Responders N (%) Non-responders N (%) P value OR (95% CI) hemodynamic response OR (95% CI) ICU mortality
Corticosteroids
Yes 251 (58.9) 320 (62.5) 0.26 0.86 (0.66–1.12) 1.01 (0.77–1.32)
Noa 175 (41.1) 192 (37.5)    
Lactate concentration
> 1.4 mmol/La 211 (78.4) 321 (88.7) < 0.001 2.15 (1.39–3.32)^ 0.39 (0.25–0.60)^
≤ 1.4 mmol/L 58 (21.6) 41 (11.3)    
BMI classification
Underweighta 18 (4.2) 20 (3.9) 0.98   
Normal 94 (22.1) 106 (20.7)   0.99 (0.50–1.97) 1.09 (0.53–2.12)
Overweight 114 (26.8) 140 (27.3)   0.90 (0.46–1.79) 1.02 (0.51–2.05)
Obesity class I 81 (19.0) 101 (19.7)   0.89 (0.44–1.80) 0.91 (0.45–1.86)
Obesity class II 48 (11.3) 53 (10.4)   1.01 (0.48–2.12) 1.13 (0.52–2.43)
Obesity class III 71 (16.7) 92 (18.0)   0.86 (0.42–1.74) 0.77 (0.37–1.57)
CA equivalent dose
≥ 15 mcg/mina 370 (86.9) 424 (82.8) 0.087 0.57 (0.36–0.92)^ 0.62 (0.44–0.89)^
< 15 mcg/min 56 (13.1) 88 (17.2)    
Total vasopressor quantity
1 Vasopressora 370 (86.9) 463 (90.4) 0.084 1.43 (0.95–2.15) 1.98 (1.26–3.12)^
> 1 Vasopressor 56 (13.1) 49 (9.6)    
Renal insufficiency
Yes 220 (51.6) 268 (52.3) 0.83 0.97 (0.75–1.26) 1.59 (1.23–2.07)^
Noa 206 (48.4) 244 (47.7)    
AKI class
No AKI presencea 258 (60.6) 308 (60.2) 0.21   
AKI-risk 29 (6.8) 50 (9.8)   0.69 (0.43–1.13) 2.40 (1.43–4.03)^
AKI-injury 11 (2.6) 21 (4.1)   0.63 (0.30–1.32) 3.30 (1.41–7.76)^
AKI-failure 67 (15.7) 75 (14.6)   1.07 (0.74–1.54) 3.06 (2.00–4.66)^
AKI-end stage 61 (14.3) 58 (11.3)   1.26 (0.85–1.87) 1.64 (1.09–2.46)^
  1. AKI acute kidney injury, BMI body mass index, CA catecholamine
  2. ^P < 0.05
  3. aThe reference group used for the odds ratio result
\